Friday, January 9, 2009

The week ends in a slide

A few of my holdings managed some gains today, despite the market slide. Not the stock that actually had news, though, which was Alnylam (12.3% of portfolio). They announced a deal with Cubist Pharmaceuticals for development of the ALN-RSV program. The deal is on the small side compared to previous partnerships, and also with a smaller-sized partner. But it still adds cash to the balance sheet, and spreads the risk of development around. It remains to be seen if the data will be positive from ALN-RSV01 trials later this year.